Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01451827

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) — NOCTURNE  

Autosomal Dominant Polycystic Kidney Disease Clinical Trial

Official title:
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Immediate-release Formulations in Subjects With Autosomal Dominant Polycystic Kidney Disease

Clinical Trial Summary

The purpose of this study is to compare the short-term effects of two tolvaptan formulations in patients with ADPKD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01451827
Study type Interventional
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact
Status Completed
Phase Phase 2
Start date October 2011
Completion date July 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02933268 - High Water Intake in Polycystic Kidney Disease N/A
Completed NCT00759369 - Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) N/A
Completed NCT00598377 - Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT01039987 - Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease N/A
Completed NCT03717883 - ADPKD Alterations in Hepatic Transporter Function
Recruiting NCT05193981 - A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
Completed NCT03487913 - The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 2
Not yet recruiting NCT06435858 - Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease Phase 4
Recruiting NCT05190744 - PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration Phase 2
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Recruiting NCT04344769 - Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Active, not recruiting NCT02848521 - A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
Completed NCT01210560 - Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Phase 2
Completed NCT01336972 - Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2
Completed NCT02134899 - The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients Phase 3
Active, not recruiting NCT02729662 - Efficacy of Tolvaptan on ADPKD Patients N/A
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05288998 - Intrarenal Microvasculature in ADPKD
Recruiting NCT04939935 - Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Phase 3
Withdrawn NCT01988038 - Repository Study of Autosomal Dominant Polycystic Kidney Disease N/A